Siemens Healthineers AG today announces its results for the second quarter of fiscal year 2025 ended March 31, 2025.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Diasorin said Tuesday that the firm's first quarter revenues jumped 8 percent year over year with growth across the company's immunodiagnostics, molecular diagnostics, and licensed technologies businesses.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025.

The 2024 annual reports of major Chinese IVD companies released.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025.

Group sales grew by 6% at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025.